A- A A+

The Global Cannabis Report

The landscape of the global cannabis industry is shifting as quickly as the legislation that underpins it. The Prohibition Partners' The Global Cannabis Report, an industry first of its kind, analyses the key developments across the global cannabis sector and provides proprietary market forecasts across the continental markets: Africa, Asia, Europe, Latin America, North America and Oceania. The report predicts that the international cannabis market could be worth up to US$103.9 billion by 2024, and outlines key commercial opportunities for international operators and investors. (prohibitionpartners.com, 2019)


USA. Nicoteen Inc.: Juul disregarded early evidence it was hooking teens 

Juul executives knew young people were flocking to its breakthrough e-cigarette shortly after it went on sale in 2015, a former manager tells Reuters. Its nicotine blend was so potent, engineers devised a kill switch to limit the dosage – but the idea was shelved. (medscape.com, 07.11.2019)


Schweiz. Schmerz, Sucht und Profit

Die Opioidkrise in den USA, das Pharmaimperium der Familie Sackler und deren Verbindungen in die Schweiz. Wie gefährlich ist das Schmerzmittel Oxycodon? (republik.ch, Schweiz, 30.10.2019)


USA. Opioidkrise in den USA Das große Feilschen kommt erst noch 

Der Vergleich in Ohio ist nur der Auftakt: Amerikas Pharmaindustrie wird für ihre Mitverantwortung an der Opioidkrise Milliarden zahlen müssen. Doch Bundesstaaten und Gemeinden streiten schon jetzt um das Geld. (Spiegel online, 22.10.2019)


USA. The Full Cost of the Opioid Crisis: $2.5 Trillion Over Four Years

October 26 marked National Prescription Drug Take Back Day, which provided Americans an opportunity to prevent drug misuse and theft by ridding their homes of potentially dangerous expired, unused, and unwanted prescription drugs. One of the most tangible examples of the dangers of misusing prescription drugs comes from the opioid crisis, which the Council of Economic Advisers (CEA) estimates cost $696 billion in 2018—or 3.4 percent of GDP—and more than $2.5 trillion for the four-year period from 2015 to 2018. These massive costs point to the nationwide economic destruction from America’s very human “crisis next door.” (The White House, 28.10.2019)


USA. Economic Impact of Non-Medical Opioid Use in the United States 

Annual Estimates and Projections for 2015 through 2019. (Society of Actuaries, USA, Oktober 2019)


USA. Nach Einstieg bei E-Zigarettenhersteller Juul: Marlboro-Konzern schreibt 4,5 Milliarden Dollar ab

Tabakkonzerne versprachen sich von der E-Zigarette Juul ein Milliardengeschäft. Für den Marlboro-Konzern Altria erwies sich das als extrem teurer Irrtum. (spiegel.de, 31.10.2019)


USA. Hospitals Take Shot at Opioid Makers Over Treating Uninsured for Addiction

While thousands of cities and counties have banded together to sue opioid makers and distributors in a federal court, another group of plaintiffs has started to sue on their own: hospitals.

Hundreds of hospitals have joined in a handful of lawsuits in state courts, seeing the state-based suits as their best hope for winning meaningful settlement money.

"The expense of treating overdose and opioid-addicted patients has skyrocketed, straining the resources of hospitals throughout our state," said Lee Bond, CEO of Singing River Health System in Mississippi in a statement. His hospital is part of a lawsuit in Mississippi. (medscape.com, 30.10.2019)


USA. Opioidkrise: Pharmaunternehmen verhandeln in den USA über Strafzahlungen

New York – Kurz vor einem wichtigen US-Prozess um süchtig machende Schmerzmittel verhandeln drei Arzneimittelgroßhändler einem Zeitungsbericht nach mit Klägeranwälten über einen milliardenschweren Vergleich. (aerzteblatt.de, 16.10.2019)


USA. Vergleich in US-Rechtsstreit um Opioidkrise erzielt

Cleveland – Im bislang größten Rechtsstreit um die Opioidkrise in den USA haben die Kläger und mehrere Unternehmen heute eine gütliche Einigung erzielt. Dies teilte ein Richter in Cleveland im Bundesstaat Ohio mit. (aerzteblatt.de, 21.10.2019)


USA. Opioidkrise in den USA: Reckitt Benckiser schließt Vergleich über 700 Millionen Dollar 

Die Pharmaindustrie soll die Opioidkrise in den USA mit mehr als 400.000 Toten ausgelöst haben. Im Streit über die Verantwortung hierfür hat mit Reckitt Benckiser nun ein weiteres Unternehmen einen Prozess abgewendet. (Spiegel online, 24.10.2019)


USA. Pharma Sells States On ‘Netflix Model’ To Wipe Out Hep C. But At What Price?

When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.

The state is paying for the marketing campaign as part of a deal to give AbbVie the exclusive right to treat its citizens who have the potentially deadly liver disease. Armed with its medication, Mavyret, AbbVie beat out rivals Merck and Gilead Sciences in a blind bidding process.

It’s the second time this year that a state has struck a novel deal with a pharmaceutical company to obtain drugs that can cure hepatitis C ― with discounts from a price that came to market at $84,000 for a course of treatment.

The drugmakers are in a race to treat the 2.4 million people in the U.S, with the viral infection.  (KHN – Kaiser Health News, USA, 25.10.2019)


USA. Trump just expanded drug testing to hundreds of thousands of workers - It’s a huge win for the drug testing industry. 

The Trump administration just made it harder for laid-off workers to get government assistance. (Vox, USA, 04.10.2019)


USA. Drug firms offer to settle U.S. opioid suits with $50 billion package: sources

Five drugmakers and distributors are offering $22 billion in cash as well as drugs and services they value at $28 billion to resolve lawsuits alleging the industry helped fuel the U.S. opioid crisis, two sources familiar with the matter told Reuters on Wednesday. (nasdaq.com, USA, 16.10.2019)


USA. Teva to Donate Over $15 Bln Worth of Drugs in Opioid Settlement - Source

Teva Pharmaceuticals is in talks to contribute over $15 billion worth of drugs as part of a settlement to resolve lawsuits alleging it helped fuel the U.S. opioid crisis, a source familiar with the matter told Reuters on Wednesday. (Reuters, 18.10.2019)


USA/Kanada. Aurora Cannabis Is Dumping Its Pot, Which May Be A Sign It’s All Over 

(…) companies like Aurora Cannabis (ACB) are “dumping” part of their harvest… because they simply grew more pot than they could sell at a reasonable price. (Forbes, USA, 21.10.2019)


USA. Four big drug firms agree to $260m opioid payout hours before trial set to begin 

Teva and three drug distributors in last-minute settlement. Firms were to be accused of profiting from addiction and death. (The Guardian, UK, 21.10.2019)


The Germany Cannabis Report

The Germany Cannabis Report is the first and only free-to-access report to focus on the biggest economy in Europe and its burgeoning cannabis market. Having legalised medical cannabis in 2017 and achieved a market value of over €73 million in 2018, Germany is set to play a central role in the European market in the coming years, which is estimated to be worth over €123 billion by 2028. (Prohibition Partners, London-Barcelona-Dublin, Oktober 2019)


Immer höhere Preise im Pharmamarkt

Pressekonferenz der Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) und des Wissenschaftlichen Instituts der AOK (WIdO) 24. September 2019, Berlin

Statement von Jürgen Klauber, Geschäftsführer des Wissenschaftlichen Instituts der AOK (WIdO)


USA. Purdue Pharma Announces Agreement in Principle on Landmark Opioid Litigation Settlement

STAMFORD, Conn., September 15, 2019. Purdue’s entire value to be contributed for the benefit of the American public. Settlement is estimated to provide more than $10 billion of value to address opioid crisis, including potentially contributing millions of doses of life-saving opioid overdose reversal medications. Purdue to use Chapter 11 reorganization to finalize and implement settlement agreement.


USA. Purdue Pharma L.P. 


USA. US-Bundesstaaten klagen gegen Millionen-Boni von Purdue Pharma

New York – Ein Bündnis von US-Bundesstaaten geht rechtlich gegen millionenschwere Boni-Pläne des umstrittenen Schmerzmittel-Herstellers Purdue Pharma vor. Es gehe um Sondervergütungen in Höhe von 38 Millionen Dollar (34,6 Mio Euro), die das Unternehmen trotz seines Insolvenzantrags auszahlen wolle, teilte New Yorks Generalstaatsanwältin Letitia James gestern mit. (aerzteblatt.de, 04.10.2019)


USA. Johnson & Johnson stimmt in US-Opioid-Krise Millionen-Vergleich zu

Washington – In der Opioid-Krise in den USA hat der Arzneimittel-Hersteller Johnson & Johnson einem Millionenvergleich zugestimmt. (...) Damit entgeht J&J einem Großprozess. (aerzteblatt.de, 02.10.2019)


USA. Purdue Pharma Settlement a “Stopgap” For Areas Hardest Hit by Opioid Crisis: Report

The proposed settlement with OxyContin maker Purdue Pharma is “no more than a stopgap for local and state governments,” which will continue to face costs related to the opioid crisis that far exceed the agreed upon amounts, according to a new report by Moody’s Investors Services. (Partnership News Service Staff, USA, 26.09.2019)


USA. House passes bill that would allow banks to work with cannabis companies

The U.S. House of Representatives voted Wednesday to advance legislation that would allow banks to provide services to cannabis companies in states where it is legal. (Reuters, 26.09.2019)


Purdue Pharma beantragt Insolvenzverfahren wegen Opioidklagen

New York – Der US-Pharmakonzern Purdue Pharma, gegen den fast 2.300 Klagen wegen seines süchtig machenden Schmerzmittels Oxycontin anhängig sind, hat Insolvenz bean­tragt. Mit dem Insolvenzverfahren nach Kapitel 11 will Purdue die Klagen beilegen, wie das Unternehmen gestern Abend in New York mitteilte. Das Unternehmen soll in eine Stiftung der öffentlichen Hand überführt werden. (aerzteblatt.de, 16.09.2019)


USA. Deals: Purdue Nearing Deal Over Opioids as 23 States Agree to Pact

Number is less than 35 sought to make bankruptcy deal easier. Purdue moves closer to filing Chapter 11 case later this month. (Bloomberg, USA, 11.09.2019)


USA. Lawsuits alone will not fix the US opioid overdose crisis

The Lancet, Volume 394, Issue 10201, 805 


USA/Kanada. In numbers: Sackler family, Purdue Pharma and the US opioid crisis

The Sacklers have become one of the world's most controversial families. (BBC, 16.09.2019)